Recent Quotes (30 days)

You have no recent quotes
chg | %

C R Bard Inc  

(Public, NYSE:BCR)   Watch this stock  
Find more results for BCR
+1.44 (0.59%)
Feb 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 243.73 - 245.43
52 week 190.52 - 245.43
Open 244.24
Vol / Avg. 0.00/665,257.00
Mkt cap 17.76B
P/E 34.88
Div/yield 0.26/0.42
EPS 7.03
Shares 72.90M
Beta 0.63
Inst. own 90%
Jan 26, 2017
Q4 2016 C R Bard Inc Earnings Release (Estimated)
Jan 10, 2017
C R Bard Inc at JPMorgan Healthcare Conference
Dec 7, 2016
C R Bard Inc at Citi Global Healthcare Conference
Nov 30, 2016
C R Bard Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 16.50% 14.31%
Operating margin 22.39% 19.02%
EBITD margin - 31.08%
Return on average assets 12.06% 10.47%
Return on average equity 37.50% 33.78%
Employees 16,300 -
CDP Score - -


730 Central Ave
United States - Map
+1-908-2778000 (Phone)
+1-908-2778412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. It operates through the manufacturing and sale of medical devices segment. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD), end-stage renal disease (ESRD) and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs.

Officers and directors

Timothy M. Ring Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Weiland President, Chief Operating Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James C. Beasley Group President
Age: 52
Bio & Compensation  - Reuters
Timothy P. Collins Group President
Age: 55
Bio & Compensation  - Reuters
John P. Groetelaars Group President
Age: 49
Bio & Compensation  - Reuters
Christopher S. Holland Chief Financial Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Samrat S. Khichi Senior Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
John A. DeFord Ph.D. Senior Vice President - Science, Technology and Clinical Affairs
Age: 54
Bio & Compensation  - Reuters
Frank Lupisella Jr. Vice President, Controller
Age: 55
Bio & Compensation  - Reuters
Betty D. Larson Vice President - Human Resources
Age: 40
Bio & Compensation  - Reuters